ESSA Pharma shares are trading lower after the company announced it terminated its Phase 2 study evaluating masofaniten combined with enzalutamide in patients with mCRPC
Portfolio Pulse from Benzinga Newsdesk
ESSA Pharma's shares dropped following the termination of its Phase 2 study on masofaniten combined with enzalutamide for mCRPC patients.
November 01, 2024 | 12:41 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
ESSA Pharma's decision to terminate its Phase 2 study on masofaniten combined with enzalutamide has led to a decline in its stock price.
The termination of a clinical trial often leads to negative investor sentiment, as it may indicate setbacks in drug development. This has likely caused the decline in ESSA Pharma's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100